Financials data is unavailable for this security.
View more
Year on year Biomerieux SA 's net income fell -20.94% from 452.30m to 357.60m despite relatively flat revenues. A contributing factor has been an increase in the selling, general and administrative costs as a percentage of sales from 26.60% to 27.77%.
Gross margin | 55.72% |
---|---|
Net profit margin | 10.48% |
Operating margin | 13.65% |
Return on assets | 7.71% |
---|---|
Return on equity | 10.98% |
Return on investment | 9.57% |
More ▼
Cash flow in EURView more
In 2023, cash reserves at Biomerieux SA fell by 195.30m. However, the company earned 445.40m from its operations for a Cash Flow Margin of 12.12%. In addition the company used 488.80m on investing activities and also paid 122.30m in financing cash flows.
Cash flow per share | 5.94 |
---|---|
Price/Cash flow per share | 17.17 |
Book value per share | 32.80 |
---|---|
Tangible book value per share | 22.25 |
More ▼
Balance sheet in EURView more
Current ratio | 2.21 |
---|---|
Quick ratio | 1.20 |
Total debt/total equity | 0.1444 |
---|---|
Total debt/total capital | 0.1258 |
More ▼
Growth rates in EUR
Year on year, growth in dividends per share remained flat while earnings per share excluding extraordinary items fell by -21.20%. Additionally when measured on a five year annualized basis, dividend per share growth ranked highest relative to its industry peers, while earnings per share growth is above the industry average.
Div yield(5 year avg) | 0.65% |
---|---|
Div growth rate (5 year) | 19.42% |
Payout ratio (TTM) | 24.46% |
EPS growth(5 years) | 6.76 |
---|---|
EPS (TTM) vs TTM 1 year ago | 6.36 |
More ▼